BiotechTube

Pembrolizumab + Flt3L + Poly ICLC

Phase 1/2UNKNOWN
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Hodgkin's Lymphoma

Conditions

Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma

Trial Timeline

Apr 5, 2019 → Mar 1, 2025

NCT ID
NCT03789097

About Pembrolizumab + Flt3L + Poly ICLC

Pembrolizumab + Flt3L + Poly ICLC is a phase 1/2 stage product being developed by Merck for Non-Hodgkin's Lymphoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT03789097. Target conditions include Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT03789097Phase 1/2UNKNOWN

Competing Products

20 competing products in Non-Hodgkin's Lymphoma

See all competitors
ProductCompanyStageHype Score
YM155 + RituximabAstellas PharmaPhase 2
52
TazemetostatEisaiPhase 2
52
ONTAKEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
ME-401Kyowa KirinPhase 1
33
ME-401Kyowa KirinPhase 2
52
gemcitabineEli LillyPhase 2
52
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
52
LY317615Eli LillyPhase 2
52
LY4584180 + RituximabEli LillyPhase 1
33
Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
77
HRS-3738Jiangsu Hengrui MedicinePhase 1
33
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
52
ABT-199 + KetoconazoleAbbViePhase 1
33
ABT-199 + RifampinAbbViePhase 1
33
[14C]ABT-199 (GDC-0199)AbbViePhase 1
33
ABT-199 + Rituximab + BendamustineAbbViePhase 1
33
ABBV-291AbbViePhase 1
33
ABT-199AbbViePhase 1
33
AvelumabMerckPhase 1
33

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85